Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Cash & Equivalents (2016 - 2021)

GT Biopharma (GTBP) has disclosed Cash & Equivalents for 11 consecutive years, with $3.9 million as the latest value for Q3 2021.

  • On a quarterly basis, Cash & Equivalents rose 1014.29% to $3.9 million in Q3 2021 year-over-year; TTM through Sep 2021 was $3.9 million, a 1014.29% increase, with the full-year FY2020 number at $5.3 million, up 18817.86% from a year prior.
  • Cash & Equivalents was $3.9 million for Q3 2021 at GT Biopharma, down from $39.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $39.5 million in Q2 2021 to a low of $5000.0 in Q1 2020.
  • A 5-year average of $4.8 million and a median of $713500.0 in 2017 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 98.22% in 2019, then surged 551000.0% in 2021.
  • GT Biopharma's Cash & Equivalents stood at $576000.0 in 2017, then skyrocketed by 113.89% to $1.2 million in 2018, then crashed by 97.73% to $28000.0 in 2019, then skyrocketed by 18817.86% to $5.3 million in 2020, then fell by 26.37% to $3.9 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Cash & Equivalents are $3.9 million (Q3 2021), $39.5 million (Q2 2021), and $27.6 million (Q1 2021).